<DOC>
	<DOCNO>NCT00625573</DOCNO>
	<brief_summary>This open-label , phase II study evaluate efficacy safety Abraxane combination Capecitabine patient metastatic colorectal cancer second third line</brief_summary>
	<brief_title>Phase II Trial Abraxane Capecitabine Metastatic Colon Cancer ( COL 01 )</brief_title>
	<detailed_description>Inclusion Criteria - Signed write informed consent - Patients histologically cytologically confirm stage IV colorectal cancer fail either irinotecan-based , oxaliplatin-based . ECOG performance status 0-2 - Presence measurable disease radiographic study ( include CT MRI scan , chest x-ray ) physical examination - At least 3 week since last major surgery . - At least 6 week since prior radiotherapy provide extent site radiotherapy field mark bone marrow suppression NOT expect . Patients receive palliative radiotherapy must recover reversible toxic effect e.g . nausea vomit cause radiation field . - At least 4 week since prior chemotherapy . - Pt reproductive potential must use effective BC Required Screening Laboratory Criteria : - Hemoglobin 9.0g/dL - WBC 3,500/mm3 [ 3.5 x 109/L ] - Neutrophils 1,500/mm3 [ 1.5 x 109/L ] - Platelets 100,000/mm3 [ 100.0 x 109/L ] - Creatinine 1.5 mg/dL ( 133 micromol/L ) AND creatinine clearance 60 mL/min • A probable life expectancy least 6 month . Exclusion Criteria - No brain metastasis . - If female childbearing potential , pregnancy test negative . - Concomitant malignancy previous malignancy colorectal cancer within last five year , exception adequately treat basal squamous cell carcinoma skin , carcinoma situ cervix , low grade prostate cancer . - Active infection . - Concurrent severe medical problem unrelated malignancy , would significantly limit full compliance study expose patient extreme risk . - Sexually active patient refuse practice adequate contraception . ( condom plus spermicide , form birth control ) - Patients condition might affect absorption oral drug ( example intermittent obstruction ) exclude unless discuss agreed principal investigator - History grade 3 4 toxicity fluoropyrimidines . - Pre-existing neuropathy ≥ NCI CTC grade 2</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Colonic Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<criteria>Signed write informed consent Patients histologically cytologically confirm stage IV colorectal cancer fail either irinotecanbased , oxaliplatinbased . ECOG performance status 02 Presence measurable disease radiographic study ( include CT MRI scan , chest xray ) physical examination At least 3 week since last major surgery . At least 6 week since prior radiotherapy provide extent site radiotherapy field mark bone marrow suppression NOT expect . Patients receive palliative radiotherapy must recover reversible toxic effect e.g . nausea vomit cause radiation field . At least 4 week since prior chemotherapy . Pt reproductive potential must use effective BC Required Screening Laboratory Criteria : Hemoglobin 9.0g/dL WBC 3,500/mm3 [ 3.5 x 109/L ] Neutrophils 1,500/mm3 [ 1.5 x 109/L ] Platelets 100,000/mm3 [ 100.0 x 109/L ] Creatinine 1.5 mg/dL ( 133 micromol/L ) AND creatinine clearance 60 mL/min A probable life expectancy least 6 month No brain metastasis . If female childbearing potential , pregnancy test negative . Concomitant malignancies previous malignancy colorectal cancer within last five year , exception adequately treat basal squamous cell carcinoma skin , carcinoma situ cervix , low grade prostate cancer . Active infection . Concurrent severe medical problem unrelated malignancy , would significantly limit full compliance study expose patient extreme risk . Sexually active patient refuse practice adequate contraception . ( condom plus spermicide , form birth control ) Patients condition might affect absorption oral drug ( example intermittent obstruction ) exclude unless discuss agreed principal investigator History grade 3 4 toxicity fluoropyrimidines . Preexisting neuropathy ≥ NCI CTC grade 2 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>Colon Cancer</keyword>
	<keyword>Abraxis Oncology</keyword>
	<keyword>Abraxane</keyword>
	<keyword>Phase II</keyword>
	<keyword>Colorectal</keyword>
	<keyword>Mt . Sinai Medical Center</keyword>
	<keyword>CCOP</keyword>
</DOC>